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Abstract
Aims: Arachidonic acid (AA) and its metabolites, prostaglandins (PG) are known to be involved in regulation of vascular
homeostasis including vascular tone and vessel wall tension, but their potential role in Hypoxic pulmonary vasoconstriction
(HPV) remains unclear. In this study, we examined the effects of AA and PGE2 on the hypoxic response in isolated rat
intrapulmonary arteries (IPAs).
Methods and Results: We carried out the investigation on IPAs by vessel tension measurement. Isotetrandrine (20 mM)
significantly inhibited phase I, phase IIb and phase IIc of hypoxic vasoconstriction. Both indomethacin (100 mM) and NS398
attenuated KPSS-induced vessel contraction and phase I, phase IIb and phase IIc of HPV, implying that COX-2 plays a
primary role in the hypoxic response of rat IPAs. PGE2 alone caused a significant vasoconstriction in isolated rat IPAs. This
constriction is mediated by EP4. Blockage of EP4 by L-161982 (1 mM) significantly inhibited phase I, phase IIb and phase IIc
of hypoxic vasoconstriction. However, AH6809 (3 mM), an antagonist of EP1, EP2, EP3 and DP1 receptors, exerted no effect
on KPSS or hypoxia induced vessel contraction. Increase of cellular cAMP by forskolin could significantly reduce KPSS-
induced vessel contraction and abolish phase I, phase II b and phase II c of HPV.
Conclusion: Our results demonstrated a vasoconstrictive effect of PGE2 on rat IPAs and this effect is via activation of EP4.
Furthermore, our results suggest that intracellular cAMP plays dual roles in regulation of vascular tone, depending on the
spatial distribution of cAMP and its coupling with EP receptor and Ca2+ channels.
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Introduction
The normal pulmonary circulation is a low pressure and low
resistance system with little or no resting vascular tone. Oxygen
tension is a major mediator in determining pulmonary vascular
tone. Unlike the systemic arterials which dilate in response to
hypoxia, the pulmonary artery constricts when oxygen tension is
lowered, a phenomenon known as hypoxic pulmonary vasocon-
striction (HPV) [1]. For example, in human subjects as well in
animals, exposure to hypoxic gas (10% O2) causes an increase in
pulmonary arterial pressure with minimal change in the left atria
pressure. HPV is restricted to the segments of the vasculature
perfusing the poorly ventilated (or hypoxic) part of the lung,
thereby maintaining an appropriate ventilation/perfusion ratio.
HPV has been demonstrated in isolated resistance pulmonary
artery rings [2] and even in isolated smooth muscle cells of the
resistance pulmonary arteries (PASMC) [3]. HPV persists after
lung denervation [4], in the absence of blood [5] and after
endothelial denudation [6], suggesting that the core mechanism of
HPV seem intrinsic to the PASMC, although it has been shown
that HPV is partly mediated by the endothelium [7–9].
Although the mechanism responsible for HPV has still not been
fully elucidated, an increase of [Ca2+]i is a primary event in the
contraction of PASMC. Ca2+ entry via voltage-gated Ca2+
channels (VGCC) [10] and voltage-independent Ca2+ channels
[11,12] have been shown to participate in HPV. On contrary, the
role of Ca2+ release from the store via Ryanodine receptors in
HPV remains controversial despite several previous reports
suggesting that Ca2+ release may be essential to HPV [13–15].
Prostaglandins (PGs) are the products of arachidonic acid (AA)
through reactions catalysed by phospholipase A2 (PLA2),
cyclooxygenase(COX) and specific terminal PG synthases. A
diverse family of PGs has been identified, including PGE2, PGF2a,
PGD2, PGI2 and thromoboxane A2 [16]. AA and its metabolites
are known to be important in regulation of local vascular tone, and
their actions are mediated by a family of 8 G protein-coupled
receptors designated EP 1–4 (for E-prostanoid receptor), FP, DP,
IP, and TP. Altered prostanoid signalling has been implicated in
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chronic pulmonary diseases. For example, COX-2 expression has
been shown to increase during hypoxia [17]. COX-2 null mice
develop severe pulmonary hypertension with enhanced endothelial
receptors. COX-2 deficient PASMCs gave a maladaptive response
to hypoxia manifested by exaggerated contractility [18], which
may be rescued by either PGI2 or PGE2. A number of prostanoid
analogs [19,20] and PG receptor antagonists [21] have been
employed in the treatment or gone into clinical trial for a variety of
vessel diseases including pulmonary hypertension. However, the
role of various prostanoids and prostanoid receptors in HPV has
not been fully delineated.
In the present study, we have evaluated the Ca2+ entry
pathways in the hypoxic response of isolated rat intrapulmonary
arteries (IPAs). The potential role of AA and its metabolite PGE2
in hypoxic vasoconstriction were explored using vessel tension
measurement. Our results demonstrate that PGE2 alone exerts
vasoconstriction in rat pulmonary artery via activation of EP4.
EP4 is involved in hypoxic vasoconstriction.
Materials and Methods
Ethics statement
Animal experiments conformed to the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (DHWE publication No. 96-01, revised in
2002) and was approved by the Ethics Review Board for Animal
Studies of Institute of Southeast University, Nanjing.
Isolated rat intrapulmonary artery (IPAs)
Male Wistar rats (250–350 g) were anaesthetized with sodium
pentobarbital (55 mg/kg, ip) and killed by cervical dislocation. Rat
lungs were quickly removed to a bath containing cold physiolog-
ical salt solution (PSS) for dissection. Small intrapulmonary
arteries (150–350 mm) were isolated from surrounding tissue, cut
as rings and mounted in a temperature controlled myograph
system (DanisMyo Technology A/S model: 610 M). The bath
solution (composition in mM: NaCl, 118; NaHCO3, 24; MgSO4,
1; NaH2PO4, 0.435; glucose, 5.56; CaCl2, 1.8; KCl, 4) was gassed
with 95% air/5% CO2 (pH 7.4) at 37uC. Each ring was initially
stretched to give an optimal pressure of 30 mmHg and the
preparation was allowed to stabilize for 60 min. A surgical thread
was pulled through the artery to obtain denuded arteries which
showed diminished relaxation response to 1 mM acetylcholine.
Hypoxic protocol
After a stabilization period of 60 min, IPAs were exposed to
high KCl-PSS (KPSS) (composition in mM: NaCl, 42; NaHCO3,
24; MgSO4, 1; NaH2PO4, 0.435; glucose, 5.56; CaCl2, 1.8; KCl,
80) for 2min duration and this was repeated three times at 10min
interval. 30 mM KPSS (in most experiments related to PG) or
5 mM of PGF2a (in most experiments related to Ca
2+ entry
pathways) was added to the solution to achieve a resting tone
equivalent to ,15% of the high KPSS response. When the resting
tone was stable, IPAs were exposed to hypoxia via bubbling the
bath solution with a gas mixture of 95% N2 + 5% CO2 for 40 min,
then washed with PSS and returned to normoxic condition.
Oxygen level (,19% in normoxia and ,2% in hypoxia) was
monitored using a dissolved oxygen meter in all experiments.
Reproducible hypoxic responses could be obtained after 60–90min
recovery time (figure1), so a standard 80 min recovery was
observed between hypoxic challenges.
Drugs
Chemicals were purchased from Biomol, except for verapamil
(Sigma) and NS398 (Calbiochem). They were dissolved in ethanol,
DMSO or distilled water as stock solution according to
manufacturer instructions. Chemicals were diluted to the final
concentration just before experiments. Ethanol and DMSO at
same concentration were without effect.
Statistical Analysis
IPA ring tension was normalized to the maximal tension
induced by 80 mM KPSS in control group. Hypoxic vasocon-
striction phase was divided as shown in figure 2a. Mean data
shown in the bar graphs were expressed as a percentage change
over the respective control. Results are shown as mean6SEM and
compared using paired Student’s t test or Nonparametric
Wilcoxon Signed Ranks test with a P value of less than 0.05
indicating statistical significance.
Results
1. Effects of Ca2+ channel blockers on hypoxia-induced
vasoconstriction in IPAs
In pilot experiments, we examined the reproducibility of the
hypoxia-induced vasoconstrictive response of IPAs and found that
consistently with a previous report [22] comparable responses
could be obtained with a recovery period of 60–90 minutes
between hypoxic episodes. Therefore, in later experiments a
standard 80 min recovery period was allowed between hypoxic
challenges. Hypoxia-induced vasoconstriction consisted of a
transient constriction (phase I) superimposed on a sustained
constriction (phase II), and phase II was divided into IIa (initial
point of phase II), IIc (termination point of phase II) and IIb
(average of time-points between IIa and IIc). Test chemicals were
applied during the second hypoxic stimulation. Prior to the second
hypoxic challenge, the basal tone was adjusted to the same level as
that in the first hypoxic challenge by adding 30–40 mM KPSS or
PGF2a (3 – 100 mM). PGF2a concentration needed to be raised in
Ca2+ free solution (100 uM) and in the presence of Verapamil
(3.5–4 uM) to achieve a pretone level [23]. To exclude the
different effects due to the different the pretone methods, 30–
Figure 1. Repeatability of hypoxic responses in rat intrapul-
monary arteries (IPAs). The IPAs were precontricted with 3–5 mM
PGF2a, which equal to about 20% of high K
+ response. The pretone was
kept constant during experiments. The hypoxia was induced by
bubbling myograph chamber with N2 balanced by 5% CO2 for 40
min, the O2 level was monitored by a dissolved oxygen meter, typically
1.5–2.5%. Then wash off by normal solution. After 1h recovery and two
exposures to high K+, same hypoxia response was induced by following
repeated protocol.
doi:10.1371/journal.pone.0073839.g001
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40 mM KPSS and PGF2a (3 – 100 mM) were tested prior to
hypoxia in one experiment, and consistent HPV was observed.
Verapamil was employed to determine the contribution of
voltage-gated Ca2+ channel (VGCC) in hypoxia-induced vasocon-
striction in IPAs. At a concentration of 10 mM (n= 5) or 40 mM
(n=6), verapamil (figure 2) almost abolished 80 mM KPSS-
induced vasoconstriction (to 13.761% and 6.161.6% of controls,
respectively), but only caused partial inhibition of the phase I
hypoxic vasoconstriction (to 63.365.9% and 54.464.3% of
controls, respectively). Neither concentrations of verapamil had
significant effect on the amplitude of the phase II hypoxic
constriction.
SKF96365 (50 mM), a non-specific Ca2+ blocker, significantly
attenuated the contractile response to 80 mM KPSS to
25.3611.7% of the control response. Hypoxia-induced vasocon-
striction was also inhibited. Thus in the presence of SKF96365,
phase I, phase II b and c of hypoxic vasoconstriction was
decreased to 38.6613%, 54.268.3% and 83.3612.3% of the
respective control value (n = 4). In contrast, 2APB (50 mM), an
inhibitor of store-operated channels, exerted no effect on KPSS-
induced contraction but inhibited phase I, phase IIb and phase II c
of hypoxic vasoconstriction to 39.567.5%, 16.967% and
16.967% of controls (n = 4).
Our result also showed that Ca2+ free bath medium (n= 4)
abolished KPSS and reduced hypoxia-induced vasoconstriction,
suggesting that Ca2+ entry plays a key role in the contractile
response of IPAs to hypoxia. In addition, the results above also
indicate that hypoxic vasoconstriction is mediated by Ca2+ entry
via both voltage dependent and voltage-independent channels.
2. Effects of blockage of AA generation on hypoxic
response in IPAs
Previously it was shown that HPV was diminished in cPLA2-
deficient mice [24], suggesting that AA and its metabolites may be
important in the hypoxic response [25]. Isotetrandrine (20 mM),
an antagonist of cPLA2, significantly inhibited phase I, phase II b
and phase II c of hypoxic vasoconstriction to 6465.7%, 78.966%
and 44.661.9% of the controls respectively (n = 6) (figure 3a)
without significant effect on KPSS-induced vasoconstriction. In
contrast, RHC 80267 (50 mM), a DAG lipase inhibitor, inhibited
KPSS-induced vasoconstriction by47.168.4% (n= 4) (figure 3b)
without significant effect on hypoxic vasoconstriction. These
results suggest that cPLA2 may be the primary pathway to
generate AA in IPAs and endothelium is the primary targeting
place by AA and its metabolites.
Figure 2. Effects of 40 mM verapamil on hypoxia induced vessel contraction in IPAs. a. Example figure of the effect of 40 mM verapamil on
high K+ and hypoxia-induced smooth muscle constriction. HPV consisted of a transient constriction (phase I) superimposed on a sustained
constriction (phase II), and phase II was divided into IIa, IIb and IIc. b. Mean data showing effect of 10 mM verapamil, 40 mM verapamil, 50 mM
SKF96365 and 50 mM 2-APB on hypoxic induced vasoconstriction in IPAs in term of percentage change in compare with corresponding parts in
control group. *, P,0.05, **, P,0.001. For 10 mM verapamil (n = 4), high K+ response and phase I hypoxic constriction reduced to 13.761% and
63.365.9% respectively. For 40 mM verapamil (n = 6), high k response and phase I hypoxic constriction reduced to 6.161.6% and 54.464.3%
respectively. SKF96365 (n = 3): high K+, phase I, phase II b and c has been reduced to 25.3611.7%, 38.6613%, 54.268.3% and 83.3612.3%
respectively. 2APB (n = 3), which has no effect on high K, reduce phase I, phase II b and c to 39.567.5%, 16.967% and 16.967% and 0 calcium
solution (n = 3)reduced high k, phase I, phase II b and c to 567%, 35.1610.4%, 58.667% and 42.160.7% of controls. All results normalized using max
vasoconstriction induced by 80 mM high k in control group.
doi:10.1371/journal.pone.0073839.g002
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3. Effects of COX inhibitors on hypoxic vasoconstriction
in IPAs
AA is converted to PGH2 by one of three isoforms of
cyclooxygenase, namely COX-1, COX-2 and COX-3. COX-1,
which is constitutively expressed has been associated with the
immediate effect of AA [26] and the basal levels of prostanoid
production. COX-2 is induced in response to inflammatory
cytokines and mediators, resulting in increased and sustained
prostanoid release. COX-3 is constitutively expressed in the
specific tissues with the highest level seen in the brain and heart.
PGH2 is converted to other prostanoids via distinct PG synthases,
for example, PGE-synthase (PGES) for PGE2.
Indomethacin (100 mM), a non-selective COX inhibitor,
diminished the phase I phase II b and phase II c hypoxic
vasoconstriction in IPAs by 90.869.3%, 97.769% and
108610%, respectively (n = 5) (figure 4a). KPSS-induced vaso-
constriction was only slightly inhibited by this concentration of
indomethacin. NS398 (10 uM), a cell-permeable selective inhibitor
of COX-2 [27], significantly attenuated phase I, phase II b and
phase II c hypoxic vasoconstriction by 59.6610%, 78.8610% and
7169% respectively (n = 5) (figure 4b), whereas valeryl salicylate
(3 mM), a selective COX-1 inhibitor, was without significant effect
on hypoxic vasoconstriction. DuP697 (25 mM), which is more
potent on COX-2 than on COX-1, attenuated phase I hypoxic
vasoconstriction by 83.2610% (n= 5) (figure 4c) without signifi-
cant effect on phase II hypoxic responses. NS398 and valeryl
salicylate, at the above concentrations, inhibited KPSS-induced
vasoconstriction by 46.2+3.2%, 23.4+6.9%, respectively. These
results suggest that products via COX-2 mediate the hypoxic
response of IPAs.
4. Effects of various EP receptor inhibitors on hypoxia-
induced vasoconstriction in IPAs
At the present, a family of 8 GPCRs have been identified to be
responsible for the diverse effects of different prostanoids. They are
designated EP 1–4 (for PGE2), FP, DP, IP, and TP, respectively.
To investigate the prostanoid receptor subtypes that are involved
in the hypoxia-induced vasoconstriction of IPAs, we utilised
different prostanoid receptor antagonists.
PGE alone caused vasoconstriction. SC-51322 (1 mM), a potent
antagonist of EP1–4 receptors, inhibited phase I hypoxic
vasoconstriction by 14.463% (n= 6) (figure 5c). At a concentra-
tion of 10 mM SC-51322 caused a strong inhibition of KPSS and
hypoxia-induced vessel contraction (figure 6c). AH6809 (3 mM),
which blocks EP1-3 but not EP4, was without effect on KPSS or
hypoxia-induced vessel contraction (n= 6) (figure 5a). These
observations suggest possible involvement of EP4 in the hypoxic
response of IPAs. This is confirmed by using L-161982, a selective
antagonist of EP4 receptor. L-161982 (1 mM) inhibited phase I,
phase II b and phase II c hypoxic vasoconstriction by 39.567.3%,
30.366.2% and 41.762.1% respectively (n = 6) (figure 5b). At this
concentration, L-161982 inhibited PGE2-induced vasoconstric-
tion by an average 69.165.6% (n= 5) without affecting KPSS-
induced contraction (figure 5d). Denuded IPAs were used to
eliminate PGs generated by endothelium. In denuded IPAs, the
effect of L161982 was similar to that on intact IPAs (figure 6b). In
Figure 3. Effects of isotetrandrine and RHC80267 on vasoconstriction of IPAs. a. Isotetrandrine, an inhibitor of cPLA2, significantly inhibited
phase I, phase II b and c of hypoxia induced vasoconstriction, but exerted no effect on KPSS induced vessel contraction. b. RHC80627, an inhibitor of
DAG lipase, exerted significant inhibition on KPSS induced vasoconstriction but no effects on hypoxic response. c. Histogram showing the effects of
isotetrandrine and RHC80267 on vasoconstriction of IPAs.
doi:10.1371/journal.pone.0073839.g003
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contrast, AH6809 which had no effect on intact IPAs, caused a
strong inhibition of the phase I, phase II a, phase II b and phase II
c hypoxic vasoconstriction by 36.4 63.6%, 78.4610%,
79.767.1% and 76.669.3% respectively (n = 6) (figure 6a). These
results suggest that PGE2 regulate vessel tone during hypoxia via
interacting with EP4 receptor.
5. Role of cAMP in hypoxic response in IPAs
Activation of EP4 has been shown to increase intracellular
cAMP via stimulating adenylatecyclase. We therefore examined
the effect of Forskolin (10 mM), an activator of adenylate cyclase
and found that it significantly reduced KPSS-induced vessel
contraction by 38.664.9%, and phase I, phase II b and phase II c
hypoxic vasoconstriction by 60.5610%, 54.2610% and
58.565.1% respectively (n = 5) (figure 7a). The inhibitory effect
of forskolin was not prevented by L-161982 (figure 7b) (n = 6).
However, SQ-22536 (85 mM), a cell-permeable adenylate cyclase
inhibitor, had no effect on KPSS or hypoxia-induced vessel
contraction (n= 6) (figure 7c), arguing against the involvement of
cAMP pathway in these responses
Previous studies have shown bradykinin stimulated PGE2
release in cultured human pulmonary artery smooth muscle cells,
which is inhibited by PI3K blocker [28]. However, in our
preparation PI3K blocker wormannin (50 nM) failed to alter the
basal vascular tone or hypoxic vasoconstriction (figure 7d).
Discussion
In this study, isolated rat IPAs exhibited biphasic contractile
responses to prolonged hypoxia (40 min), consisting of a transient
phase I constriction superimposed on a sustained phase II
constriction, which has been shown to be endothelium-dependent.
Using different Ca2+ channel blockers, we show that Ca2+ entry
via voltage-gated and voltage-independent channels were both
important in hypoxic vasoconstriction. Inhibitors of AA generation
via cPLA2 or prostanoid synthesis via COX-2 significantly
attenuated hypoxia-induced vessel contraction. PGE alone could
initiate vasoconstriction. Antagonists that had efficacy on EP4
receptor could partly inhibit the hypoxic response. These
observations suggest that AA metabolites are important players
in regulation of hypoxic vasoconstriction and that EP4 appear to
be involved.
In order to examine the contributions of Ca2+ entry pathways in
the hypoxic vasoconstriction of IPAs, we applied varying
concentrations of PGF2a to adjust the baseline vessel tension to
the same level. Previous studies have shown that 0.1–1 mM PGF2a
resulted in a transient followed by a plateau rise in [Ca2+]i [29] via
activation of FP receptor. This [Ca2+]i elevation was composed of
Ca2+ release from store and Ca2+ entry via store operated Ca2+
entry (SOC). Higher concentrations (10 mM) of PGF2a led to Ca
2+
entry via L-type VGCCs and receptor operated Ca2+ channels as
Figure 4. Effect of blockage of COX on hypoxic vasoconstriction in IPAs. a. Indomethacin, a nonspecific antagonist of COX, almost abolished
hypoxic vasoconstriction in IPAs and exerted slight inhibition on KPSS induced vessel contraction. b. NS398, a specific antagonist of COX-2, abolished
phase II of hypoxic vasoconstriction and significantly inhibited phase I of hypoxic vasoconstriction. c. DuP697, a highly selective and irreversible
inhibitor of COX-2, abolished phase I of hypoxic vasoconstriction. d. Valeryl Salicylate, a highly selective antagonist of COX-1, attenuated KPSS
induced vessel contraction.
doi:10.1371/journal.pone.0073839.g004
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a result of TP receptor activation. Noticeably, the presence of
varying concentrations of PGF2a may have influence on the
hypoxic responses and thus may bias interpretation of our data,
when experiments were performed to investigate effects of EPs.
We therefore have performed experiments by using varying
concentrations of KPSS (30–40 mM KCl) to adjust the baseline
tone. In addition, vessel contraction elicited by 80 mM KPSS
prior to and after application of chemicals was compared. The
significant difference in KPSS response with or without tested
chemicals indicates the modulation of VGCCs by applied
chemicals.
Consistent with previous reports [23], our results also show
incubation in Ca2+-free bath medium abolished hypoxic vasocon-
striction in the rat IPAs, confirming the key role of Ca2+ entry in
the hypoxic response. 2-APB and SKF96365 were employed to
identify the role of Ca2+ entry via voltage-independent channels in
hypoxic vasoconstriction. They both exert an inhibitory effect on
voltage independent Ca2+ influx. SKF-96365 not only inhibits
voltage-independent Ca2+ entry e.g. TRP channel, but also
attenuates voltage dependent Ca2+ entry, which is interpreted by
its effect on decrease of 80 KPSS induced vasoconstriction, as
vearapmil almost abolishes the 80 mM KPSS induced vasocon-
striction. 2 APB as a membrane permeable SOCE inhibitor exerts
no effect on KPSS induced contraction but attenuates hypoxic
phase I and phase II constriction. In conclusion, SKF96365 works
on both voltage dependent and voltage independent Ca2+ entry.
2APB in dosage (50 mM) has more specificity on SOCE. In
addition to VGCC, voltage independent Ca2+ entry contributes to
HPV. It is noticeable that SKF96365 exerted a similar inhibition
effect in the phase I of HPV as 2-APB performed, but had less
inhibition in the phase II of HPV than 2-APB did. It is well
documented that phase II of HPV is endothelium dependent and
voltage-independent Ca2+ channel is predominant in endotheli-
um, suggesting that SKF96365 in compare with 2APB is less
favour on voltage-independent Ca2+entry.
A variety of lipids including AA and its metabolites have been
demonstrated to activate and/or modulate diverse channels
including K channels [30], VGCCs [10,31] and TRP channels
[32,33]. In our previous study, we have shown exogenous AA
could attenuate hypoxia-induced Ca2+ elevation in cultured
human pulmonary artery smooth muscle cells via inhibition on
voltage-independent Ca2+ entry [34]. Here we show that in the rat
IPAs, hypoxic vasoconstriction was inhibited by a blocker of
cPLA2 which is involved in the production of AA. This
observation is consistent with the observation on cPLA2 knockout
mice which had diminished hypoxic pulmonary vasoconstrictitive
responses [24] and suggest that endogenous AA is a mediator
promoting hypoxic vasoconstriction in the rat pulmonary vessels.
In addition, we found that DAG lipase inhibitors had no effect on
the hypoxic response. Therefore, it appears that in the rat IPAs,
AA largely derives from cPLA2 pathway.
Figure 5. Effects of various EP receptor inhibitors on hypoxic vasoconstriction in IPAs. a. AH6809, a general blocker of EP1, EP2, EP3 and
DP1 receptors, exerted no effect on hypoxic vasoconstriction. b. L-161982, an antagonist of EP4, significantly inhibited phase I and phase II b and c. c.
SC-51322, an antagonist of EP1 receptor, inhibited phase I of hypoxic vasoconstriction. d. L-161982 inhibited PGE induced vasoconstriction but not
KPSS induced vessel contraction.
doi:10.1371/journal.pone.0073839.g005
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Two major isoforms of COX have been identified in rat
pulmonary artery, namely COX-1 and COX-2. COX1 is
constitutively expressed and is associated with the basal level of
prostanoid. Its product PGH2 is converted to PGE2 by cytosolic
PGEs (cPGEs). COX-2 is induced in response to inflammatory
cytokines and mediators, resulting in increased and sustained
prostanoid release. PGH2 produced by COX-2 is converted to
PGE2 via microsomal PGEs (mPGEs). We found that the non-
selective COX inhibitor indomethacin significantly inhibited
hypoxic vasoconstriction in rat IPAs and this effect was mimicked
by the COX-2 selective inhibitor NS398. However, DuP697 only
inhibit phase I responses, suggesting that COX-2-mPGEs-PGE2
pathway plays a primary role in regulating rat pulmonary arterial
tone during hypoxia at least in phase I. The difference derived
from the two cox-2 inhibitors is likely due to NS398 binding within
the cyclooxygenase channel of COX-2 in a similar fashion to
indomethacin, but in a different position for other COX-2-
selective inhibitors [35]. In addition, NS398 is the specific blocker
for COX-2 but DuP697 has effects on both COX2 and COX1.
COX-1 and COX-2 are of similar molecular weight and have
65% amino acid sequence homology and near-identical catalytic
sites. The selective inhibition is the substitution of isoleucine at
position 523 in COX-1 with valine in COX-2. Drug molecules,
such as DuP-697, bind to the alternative site to be considered in
selective COX1 andCOX-2. Valeyl Salicylate which is a specific
blocker of COX1 had little effect on HPV. It may suggested
COX2 plays a key role in regulation of HPV. With respect to the
different COX selectivity between NS398 and DuP697, different
inhibition effects derived from them on the phase II of HPV
implicated the expression COX2 may be higher in endothelium.
The messengers released from endothelium regulate the signaling
pathways of smooth muscle cells and profoundly contribute to
HPV.
We further explored the prostanoid receptor subtypes that
might be involved in hypoxic vasoconstriction in rat IPAs. We
found that prostanoid receptor antagonists with efficacy on EP4
inhibited hypoxic vasoconstriction, whereas inhibitors of EP1-3
exerted no effect. AH6809 inhibited phase II in denuded IPAs,
and it may be contributed by the lower pretone in the presence of
AH6809. These results implicated that endogenous prostanoids,
presumably PGE2 regulate vessel tone during hypoxia via
interacting with EP4 receptor.
Activation of EP4 is reported to be coupled with an increase of
cellular cAMP via Gs [26]. We therefore examined the possible
role of cAMP in hypoxic vasoconstriction in IPAs. Surprisingly,
forskolin, an activator of adenylyl cyclase caused significant
attenuation of KPSS and hypoxia-induced vasoconstriction in
rat IPAs, suggesting that a global cAMP elevation induced by
forskolin, affected both voltage-dependent and voltage-indepen-
dent Ca2+ channel [36]. In summary, we found that in the isolated
rat IPAs, prostanoid signal pathway is an important mechanism in
control of vessel tone during hypoxia. Upon hypoxia, AA
produced via cPLA2 was broken down to PGE2 via COX-2
and mPGE pathway, and that PGE2 interact with EP4 leading to
Figure 6. Effect of AH6809 and L161982 on hypoxic pulmonary vasoconstriction in denuded IPAs. a. Transient hypoxic vasoconstriction
was suppressed by AH6809, and L-161982. b. Histogram showing the effects of different dosages of chemicals above on hypoxic pulmonary
vasoconstriction.
doi:10.1371/journal.pone.0073839.g006
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consequently vasoconstriction. ONO-AE-248 (EP3 agonist) in-
duces vessel contraction [38] in human pulmonary artery, but EP3
antagonist exerts no effect on isolated rat IPAs, suggesting the
different mechanisms underlining the vasoconstriction by PGE in
different species [37]. The contracted human pulmonary arteries
fail to dilate when they are challenged with PGE2 [39]. In
addition, relaxation in human pulmonary vein by prostnoids
involves DP, IP receptors and EP receptors. These observations
signify the profound and complex role of prostanoid signaling in
control of pulmonary vessel tone in different situations and species.
Author Contributions
Conceived and designed the experiments: GM YG CT. Performed the
experiments: GY YH QW HS. Analyzed the data: GY YH CT.
Contributed reagents/materials/analysis tools: YG GM CT. Wrote the
paper: GY YH YG CT.
References
1. Sylvester JT, Shimoda LA, Aaronson PI, Ward JPT (2012) HYPOXIC
PULMONARY VASOCONSTRICTION. Physiological Reviews 92: 367–520.
2. Moudgil R, Michelakis ED, Archer SL (2005) Hypoxic pulmonary vasocon-
striction. Journal of Applied Physiology 98: 390–403.
3. Waypa GB, Marks JD, Guzy R, Mungai PT, Schriewer J, et al. (2010) Hypoxia
Triggers Subcellular Compartmental Redox Signaling in Vascular Smooth
Muscle Cells. Circulation Research 106: 526–535.
4. Miniati DN, Robbins RC (2000) Mechanical support for acutely failed heart or
lung grafts. Journal of Cardiac Surgery 15: 129–135.
5. Madden JA, Ahlf SB, Dantuma MW, Olson KR, Roerig DL (2012) Precursors
and inhibitors of hydrogen sulfide synthesis affect acute hypoxic pulmonary
vasoconstriction in the intact lung. Journal of Applied Physiology 112: 411–418.
6. Weigand L, Shimoda LA, Sylvester JT (2011) Enhancement of myofilament
calcium sensitivity by acute hypoxia in rat distal pulmonary arteries. American
Journal of Physiology-Lung Cellular and Molecular Physiology 301: L380–L387.
7. Aaronson PI, Robertson TP, Ward JPT (2002) Endothelium-derived mediators
and hypoxic pulmonary vasoconstriction. Respiratory Physiology & Neurobiol-
ogy 132: 107–120.
8. Robertson TP, Aaronson PI, Ward JPT (2003) Ca2+ sensitization during
sustained hypoxic pulmonary vasoconstriction is endothelium dependent.
American Journal of Physiology-Lung Cellular and Molecular Physiology 284:
L1121–L1126.
9. Robertson TP (2007) Point : Counterpoint: Release of an endothelium-derived
vasoconstrictor and RhoA/Rho kinase-mediated calcium sensitization of smooth
muscle cell contraction are/are not the main effectors for full and sustained
hypoxic pulmonary vasoconstriction. Journal of Applied Physiology 102: 2071–
2079.
10. Weir EK, Olschewski A (2006) Role of ion channels in acute and chronic
responses of the pulmonary vasculature to hypoxia. Cardiovascular Research 71:
630–641.
11. Weissmann N, Dietrich A, Fuchs B, Kalwa H, Ay M, et al. (2006) Classical
transient receptor potential channel 6 (TRPC6) is essential for hypoxic
pulmonary vasoconstriction and alveolar gas exchange. Proc Natl Acad Sci U
S A 103: 19093–19098.
12. Beech DJ (2005) Emerging functions of 10 types of TRP cationic channel in
vascular smooth muscle. Clin Exp Pharmacol Physiol 32: 597–603.
13. Becker S, Moir LM, Snetkov VA, Aaronson PI (2007) Hypoxic pulmonary
vasoconstriction in intact rat intrapulmonary arteries is not initiated by
inhibition of Na+-Ca2+ exchange. American Journal of Physiology-Lung
Cellular and Molecular Physiology 293: L982–L990.
14. Wang J, Weigand L, Foxson J, Shimoda LA, Sylvester JT (2007) Ca2(+)
signaling in hypoxic pulmonary vasoconstriction: effects of myosin light chain
and Rho kinase antagonists. American Journal of Physiology-Lung Cellular and
Molecular Physiology 293: L674–L685.
Figure 7. Hypoxic vasoconstriction in IPAs was independent on PIK3 but attenuated by cellular cAMP. a. Forskolin significantly
inhibited the phase I, phase II b and c of vasoconstriction respectively. b. Forskolin with L161982 further attenuated hypoxic vasoconstriction in IPAs.
c. SQ-22536, an inhibitor of cAMP production induced by PGE1, exerted no effect on either KPSS or hypoxia induced vessel contraction. d.
Wortmannin, an antagonist of PI3K, exerted no effect on vessel contraction.
doi:10.1371/journal.pone.0073839.g007
PGE2 Regulates HPV by Activation of EP4 in Hypoxia
PLOS ONE | www.plosone.org 8 August 2013 | Volume 8 | Issue 8 | e73839
15. Li XQ, Zheng YM, Rathore R, Ma J, Takeshima H, et al. (2009) Genetic
evidence for functional role of ryanodine receptor 1 in pulmonary artery smooth
muscle cells. Pflugers Archiv-European Journal of Physiology 457: 771–783.
16. Ricciotti E, FitzGerald GA (2011) Prostaglandins and Inflammation. Arterio-
sclerosis Thrombosis and Vascular Biology 31: 986–1000.
17. Bradbury DA, Newton R, Zhu YM, Stocks J, Corbett L, et al. (2002) Effect of
bradykinin, TGF-beta 1, IL-1 beta, and hypoxia on COX-2 expression in
pulmonary artery smooth muscle cells. American Journal of Physiology-Lung
Cellular and Molecular Physiology 283: L717–L725.
18. Fredenburgh LE, Liang OD, Macias AA, Polte TR, Liu X, et al. (2008) Absence
of cyclooxygenase-2 exacerbates hypoxia-induced pulmonary hypertension and
enhances contractility of vascular smooth muscle cells. Circulation 117: 2114–
2122.
19. Oudiz RJ, Farber HW (2009) Dosing considerations in the use of intravenous
prostanoids in pulmonary arterial hypertension: An experience-based review.
American Heart Journal 157: 625–635.
20. Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, et al.
(2011) Long-term effects of inhaled treprostinil in patients with pulmonary
arterial hypertension: The TReprostinil sodium Inhalation Used in the
Management of Pulmonary arterial Hypertension (TRIUMPH) study open-
label extension. Journal of Heart and Lung Transplantation 30: 1327–1333.
21. Safdar Z (2009) Outcome of pulmonary hypertension subjects transitioned from
intravenous prostacyclin to oral bosentan. Respiratory Medicine 103: 1688–
1692.
22. Frazziano G, Moreno L, Moral-Sanz J, Menendez C, Escolano L, et al. (2011)
Neutral Sphingomyelinase, NADPH Oxidase and Reactive Oxygen Species.
Role in Acute Hypoxic Pulmonary Vasoconstriction. Journal of Cellular
Physiology 226: 2633–2640.
23. Robertson TP, Hague D, Aaronson PI, Ward JP (2000) Voltage-independent
calcium entry in hypoxic pulmonary vasoconstriction of intrapulmonary arteries
of the rat. J Physiol 525 Pt 3: 669–680.
24. Ichinose F, Ullrich R, Sapirstein A, Jones RC, Bonventre JV, et al. (2002)
Cytosolic phospholipase A(2) in hypoxic pulmonary vasoconstriction. J Clin
Invest 109: 1493–1500.
25. Eyster KM (2007) The membrane and lipids as integral participants in signal
transduction: lipid signal transduction for the non-lipid biochemist. Adv Physiol
Educ 31: 5–16.
26. Norel X (2007) Prostanoid receptors in the human vascular wall. Scientific-
WorldJournal 7: 1359–1374.
27. Ramos-Alves FE, de Queiroz DB, Santos-Rocha J, Duarte GP, Xavier FE (2012)
Increased cyclooxygenase-2-derived prostanoids contributes to the hyperreac-
tivity to noradrenaline in mesenteric resistance arteries from offspring of diabetic
rats. PLoS One 7: e50593.
28. Bradbury DA, Corbett L, Knox AJ (2004) PI 3-kinase and MAP kinase regulate
bradykinin induced prostaglandin E(2) release in human pulmonary artery by
modulating COX-2 activity. FEBS Lett 560: 30–34.
29. Snetkov VA, Knock GA, Baxter L, Thomas GD, Ward JP, et al. (2006)
Mechanisms of the prostaglandin F2alpha-induced rise in [Ca2+]i in rat
intrapulmonary arteries. J Physiol 571: 147–163.
30. Oliver D, Lien CC, Soom M, Baukrowitz T, Jonas P, et al. (2004) Functional
conversion between A-type and delayed rectifier K+ channels by membrane
lipids. Science 304: 265–270.
31. Jakoubek V, Bibova J, Hampl V (2006) Voltage-gated calcium channels mediate
hypoxic vasoconstriction in the human placenta. Placenta 27: 1030–1033.
32. Harteneck C (2005) Function and pharmacology of TRPM cation channels.
Naunyn Schmiedebergs Arch Pharmacol 371: 307–314.
33. Grimm C, Kraft R, Schultz G, Harteneck C (2005) Activation of the melastatin-
related cation channel TRPM3 [corrected] by D-erythro-sphingosine. Mol
Pharmacol 67: 798–805.
34. Meng F, To WK, Gu Y (2008) Inhibition effect of arachidonic acid on hypoxia-
induced [Ca(2+)](i) elevation in PC12 cells and human pulmonary artery smooth
muscle cells. Respir Physiol Neurobiol 162: 18–23.
35. Vecchio AJ, Malkowski MG (2011) The structure of NS-398 bound to
cyclooxygenase-2. J Struct Biol 176: 254–258.
36. Yang SN, Yu J, Mayr GW, Hofmann F, Larsson O, et al. (2001) Inositol
hexakisphosphate increases L-type Ca2+ channel activity by stimulation of
adenylyl cyclase. Faseb J 15: 1753–1763.
37. Foudi N, Kotelevets L, Louedec L, Leseche G, Henin D, et al. (2008)
Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of
the EP4 receptor subtype. Br J Pharmacol 154: 1631–1639.
38. Norel X, de Montpreville V, Brink C (2004) Vasoconstriction induced by
activation of EP1 and EP3 receptors in human lung: effects of ONO-AE-248,
ONO-DI-004, ONO-8711 or ONO-8713. Prostaglandins Other Lipid Mediat
74: 101–112.
39. Walch L, Labat C, Gascard JP, de Montpreville V, Brink C, et al. (1999)
Prostanoid receptors involved in the relaxation of human pulmonary vessels. Br J
Pharmacol 126: 859–866.
PGE2 Regulates HPV by Activation of EP4 in Hypoxia
PLOS ONE | www.plosone.org 9 August 2013 | Volume 8 | Issue 8 | e73839
